KPCB’s James Huang Says High Healthcare Valuations Force Investors To Seek Early Stage Innovation

Login to View

Listen: "KPCB’s James Huang Says High Healthcare Valuations Force Investors To Seek Early Stage Innovation"


China’s healthcare sector is seeing a flood of new capital from from non-professional investors such as Chinese coal mining and factory bosses, according to James Huang, a managing partner at Kleiner Perkins Caufield & Byers (KPCB) China, who focuses on life sciences. As a result, valuations have become excessive, forcing more experienced investors to adopt new strategies to get ahead of the "dumb money."

Continue reading with a China Money Network subscription


Join Now

Already have an account or paid subscription? Log in


RELATED NEWS



LEAVE A REPLY

Please enter your comment!
Please enter your name here